Variations in cause and management of atrial fibrillation in a prospective registry of 15 400 emergency department patients in 46 countries: The RE-LY atrial fibrillation registry

Circulation

Volumn 129, Issue 15, 2014, Pages 1568-1576

  Oldgren, Jonas ^a   Healey, Jeff S ^b   Ezekowitz, Michael ^c,d   Commerford, Patrick ^e   Avezum, Alvaro ^f   Pais, Prem ^g   Zhu, Jun ^h   Jansky, Petr ⁱ   Sigamani, Alben ^g   Morillo, Carlos A ^b   Liu, Lisheng ^h   Damasceno, Albertino ^j   Grinvalds, Alex ^b   Nakamya, Juliet ^b   Reilly, Paul A ^k   Keltai, Katalin ^l   Van Gelder, Isabelle C ^m   Yusufali, Afzal Hussein ⁿ   Watanabe, Eiichi ^o   Wallentin, Lars ^a   Connolly, Stuart J ^b   Yusuf, Salim ^b   more..

^a UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^b MCMASTER UNIVERSITY   (Canada)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f Instituto de Cardiologia Dante Pazzanese   (Brazil)

^g ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^h FUWAI HOSPITAL   (China)

ⁱ UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^j EDUARDO MONDLANE UNIVERSITY   (Mozambique)

^k BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^l SEMMELWEIS UNIVERSITY   (Hungary)

^m UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁿ DUBAI HEALTH AUTHORITY   (United Arab Emirates)

^o FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

anticoagulants; atrial fibrillation; epidemiology; hypertension; registries

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DISOPYRAMIDE; DIURETIC AGENT; DOFETILIDE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROPAFENONE; QUINIDINE; SOTALOL; TICLOPIDINE; VERAPAMIL; WARFARIN;

AFRICA; AGED; ANTICOAGULANT THERAPY; ARTICLE; CHADS2 SCORE; CHINA; COMORBIDITY; DISEASE PREDISPOSITION; EASTERN EUROPE; EMERGENCY WARD; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INDIA; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PREVALENCE; PRIORITY JOURNAL; RHEUMATIC HEART DISEASE; RISK FACTOR; SOUTHEAST ASIA;

ANTICOAGULANTS; ATRIAL FIBRILLATION; EPIDEMIOLOGY; HYPERTENSION; REGISTRIES;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASIA; ATRIAL FIBRILLATION; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; HYPERTENSION; INTERNATIONALITY; MALE; MIDDLE AGED; NORTH AMERICA; PREVALENCE; REGISTRIES; RHEUMATIC HEART DISEASE; RISK ASSESSMENT; RISK FACTORS; SOCIOECONOMIC FACTORS; WORLD HEALTH;

EID: 84899050921     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.005451     Document Type: Article

References (41)

1. Furberg CD, Psaty BM, Manolio TA. The prevalence of atrial fbrillation in elderly subjects. Am J Cardiol. 1994;74:236-241.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fbrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
3. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fbrillation: the Framingham study. N Engl J Med. 1982;306:1018-1022.
4. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fbrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N-9N.
5. Krahn AD. The natural history of atrial fbrillation: Incidence, risk factors and prognosis in the Mainitoba Follow-up Study. Am J Med. 1995;98:476-84.
6. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt G, Le Heuzey JY, Prins MH, Lévy S, Crijns HJ. Atrial fbrillation management: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422-2434.
7. Ntep-Gweth M, Zimmermann M, Meiltz A, Kingue S, Ndobo P, Urban P, Bloch A. Atrial fbrillation in Africa: clinical characteristics, prognosis, and adherence to guidelines in Cameroon. Europace. 2010;12:482-487.
8. Zubaid M, Rashed WA, Alsheikh-Ali AA, Almahmeed W, Shehab A, Sulaiman K, Al-Zakwani I, Alqudaimi A, Asaad N, Amin H; Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Investigators. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE): design and baseline characteristics of patients with atrial fbrillation in the Arab Middle East. Circ Cardiovasc Qual Outcomes. 2011;4:477-482.
9. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A. Absolute and attributable risks of atrial fbrillation in relation to optimal and borderline risk factors. Circulation. 2011;123:1501-8.
10. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fbrillation. N Engl J Med. 2002;347:1825-1833.
11. Nair GM, Nery PB, Diwakaramenon S, Healey JS, Connolly SJ, Morillo CA. A systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial fbrilla-tion. J Cardiovasc Electrophysiol. 2009;20:138-144.
12. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fbrillation. Ann Intern Med. 2007;146:857-867.
13. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fbrillation. N Engl J Med. 2011;364:806-817.
14. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fbrillation. N Engl J Med. 2011;365:981-992.
15. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fbrillation. N Engl J Med. 2011;365:883-891.
16. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fbrillation. N Engl J Med. 2009;361:1139-1151.
17. Gao Q, Fu X, Wei JW, Chen X, Huang J, Anderson CS, Wong KS. Use of oral anticoagulation among stroke patients with atrial fbrillation in China. Int J Stroke. 2013;8:150-4.
18. World Bank list of economies 2011. http://wdronline.worldbank.org/ worldbank/a/incomelevel. Accessed April 2, 2012.
19. Conen D, Tedrow UB, Cook NR, Moorthy MV, Buring JE, Albert CM. Alcohol consumption and risk of incident atrial fbrillation in women. JAMA. 2008;300:2489-2496.
20. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classifcation schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
21. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fbrillation-executive summary. J Am Coll Cardiol. 2006;48:854-906.
22. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulation therapy. Thromb Haemost. 1993;69:412-417.
23. Quinn RR, Hemmelgarn BR, Padwal RS, Myers MG, Cloutier L, Bolli P, McKay DW, Khan NA, Hill MD, Mahon J, Hackam DG, Grover S, Wilson T, Penner B, Burgess E, McAlister FA, Lamarre-Cliche M, McLean D, Schiffrin EL, Honos G, Mann K, Tremblay G, Milot A, Chockalingam A, Rabkin SW, Dawes M, Touyz RM, Burns KD, Ruzicka M, Campbell NR, Vallée M, Prasad GV, Lebel M, Tobe SW. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension. Can J Cardiol. 2010;26:241-8.
24. O'Reilly DJ, Hopkins RB, Healey JS, Dorian P, Sauriol L, Tarride JE, Burke N, Goeree RA. The burden of atrial fbrillation on the hospital sector in Canada. Can J Cardiol. 2013;29:229-235.
25. Webb R, Wilson NJ, Lennon D. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med. 2007;357:470-6.
26. Saxena A, Ramakrishnan S, Roy A, Seth S, Krishnan A, Misra P, Kalaivani M, Bhargava B, Flather MD, Poole-Wilson PP. Prevalence and outcome of subclinical rheumatic heart disease in India: the Rheumatic Study. Heart. 2011;97:2018-2022.
27. Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. Lancet. 2012;379:953-964.
28. Viali S, Saena P, Futi V. Rheumatic Fever Programme in Samoa. N Z Med J. 2011;124:26-35.
29. Carapetis JR, Zühlke LJ. Global research priorities in rheumatic fever and rheumatic heart disease. Ann Pediatr Cardiol. 2011;4:4-12.
30. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P. Selecting patients with atrial fbrillation for anticoagu-lation: stroke risk stratifcation in patients taking aspirin. Circulation. 2004;110:2287-2292.
31. Lamassa M, Di Carlo A, Pracucci G, Basile AM, Trefoloni G, Vanni P, Spolveri S, Baruff MC, Landini G, Ghetti A, Wolfe CD, Inzitari D. Characteristics, outcome, and care of stroke associated with atrial fbril-lation in Europe: data from a multicenter multinational, hospital-based registry. Stroke. 2001;32:392-8.
32. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fbrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952.
33. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fbrillation and heart failure. N Engl J Med. 2008;358:2667-2677.
34. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fbrillation. J Am Coll Cardiol. 2007;50:309-315.
35. You JH, Chan FW, Wong RS, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol. 2005;59:582-587.
36. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S. Beneft of oral anticoagulant over antiplatelet therapy in atrial fbrillation depends on the quality of international normalized ratio control achieved by centres and countries as measured by time in therapeutic range. Circulation. 2008;118:2029-2037.
37. Nieuwlaat R, Connolly SJ, Mackay JA, Weise-Kelly L, Navarro T, Wilczynski NL, Haynes RB. Computerized clinical decision support systems for therapeutic drug monitoring and dosing; A decision-maker-researcher partnership systematic review. Implement Sci. 2011;6:90.
38. ACTIVE Investigators, Connolly SJ, Pogue J Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fbrillation. N Engl J Med. 2009;30:2066-78.
39. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fbrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840-844.
40. Le Heuzey JY, Breithardt G, Camm J, Crijns H, Dorian P, Kowey PR, Merioua I, Prystowsky EN, Schwartz PJ, Torp-Pedersen C, Weintraub W. The RecordAF study: design, baseline data, and profle of patients according to chosen treatment strategy for atrial fbrillation. Am J Cardiol. 2010;105:687-693.
41. Millar RN, Mayosi BM. Utilization of implantable defbrillators in Africa. Card Electrophysiol Rev. 2003;7:14-16.